Login
$CBLL
$26.42 +$0.28 (1.07%) Live

$CBLL 8-K SEC Filings

Filed On Filing
03 Nov 2026 8-K: Results of Operations and Financial Condition

Sunnyvale, Calif. – November 3, 2026 – CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financi...

10 Aug 2026 8-K: Results of Operations and Financial Condition

Sunnyvale, Calif. – August 10, 2026 – CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financia...

30 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

02 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

The 2026 Annual Meeting of Stockholders (the “Meeting”) of CeriBell, Inc. (the “Company”) was held on June 2, 2026. At the Meeting, the Company’s stockholders voted on the following two proposals and cast their votes as described below.

11 May 2026 8-K: Results of Operations and Financial Condition

Sunnyvale, Calif. – May 11, 2026 – CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial r...

24 Feb 2026 8-K: Results of Operations and Financial Condition

Sunnyvale, Calif. – February 24, 2026 – CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financ...

05 Jan 2026 8-K: Other Events

Clearance would position the Ceribell System as the first and only point-of-care electroencephalography (EEG) technology to aid in detection and monitoring of Large Vessel Occlusion (LVO) stroke in the hospital setting

02 Jan 2026 8-K: Departure/Election of Directors or Officers; Compensation

Rebecca RobertsonBoard ChairCeribell360 N Pastoria AvenueSunnyvale, CA 94085, USA

12 Dec 2025 8-K: Entry into a Material Definitive Agreement

Certain identified information contained in this document, marked by [***], has been omitted from the exhibit pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is both (i) not material and (ii) the type of information that the...

09 Dec 2025 8-K: Other Events

Novel technology paves the way for use of the company's industry-leading point-of-care electroencephalography (EEG) system to address long unmet need in delirium monitoring

24 Nov 2025 8-K: Other Events

Becomes the first and only FDA-cleared seizure detection algorithm for pre-term neonates through adults enabling rapid bedside detection, diagnosis, and treatment of non-convulsive seizures

04 Nov 2025 8-K: Results of Operations and Financial Condition

SUNNYVALE, Calif., November 4, 2025 – CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financia...

24 Sep 2025 8-K: Entry into a Material Definitive Agreement

Certain identified information contained in this document, marked by [***], has been omitted from the exhibit pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is both (i) not material and (ii) the type of information that the...

22 Sep 2025 8-K: Departure/Election of Directors or Officers; Compensation

Accomplished innovator and healthcare executive brings proven strategic leadership and expertise in scaling high-growth healthcare companies

05 Aug 2025 8-K: Results of Operations and Financial Condition

SUNNYVALE, Calif., August 5, 2025 – CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial ...

07 Jul 2025 8-K: Other Events

Ceribell Files Complaints Against Natus Medical Incorporated with the U.S. International Trade Commission and Federal Court in Delaware

20 Jun 2025 8-K: Entry into a Material Definitive Agreement

Certain confidential information contained in this document, marked by [***], has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is both (i) not material and (ii) the type of information that the registrant tre...

12 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

The 2025 Annual Meeting of Stockholders (the “Meeting”) of Ceribell, Inc. (the “Company”) was held on June 10, 2025. At the Meeting, the Company’s stockholders voted on the following two proposals and cast their votes as described below.

08 May 2025 8-K: Results of Operations and Financial Condition

SUNNYVALE, Calif., May 8, 2025 – CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial res...

11 Apr 2025 8-K: Regulation FD Disclosure

The U.S. government has recently announced a broad range of tariffs (“incremental tariffs”) on goods imported into the United States. In response to apparent market uncertainty, CeriBell, Inc. (“Ceribell” or the “Company”) is providing e...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support